HighTower Advisors LLC boosted its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 89.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 31,666 shares of the company's stock after purchasing an additional 14,958 shares during the period. HighTower Advisors LLC owned about 0.06% of Prestige Consumer Healthcare worth $2,473,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Prestige Consumer Healthcare by 7.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,053 shares of the company's stock worth $863,000 after purchasing an additional 731 shares in the last quarter. Amundi grew its stake in Prestige Consumer Healthcare by 187.4% in the 4th quarter. Amundi now owns 25,669 shares of the company's stock valued at $1,909,000 after buying an additional 16,737 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Prestige Consumer Healthcare by 5.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,276 shares of the company's stock valued at $412,000 after acquiring an additional 296 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $42,593,000. Finally, Proficio Capital Partners LLC bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth $1,689,000. 99.95% of the stock is owned by institutional investors.
Prestige Consumer Healthcare Price Performance
Prestige Consumer Healthcare stock traded down $0.03 during mid-day trading on Wednesday, hitting $84.97. 297,642 shares of the company traded hands, compared to its average volume of 259,499. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. Prestige Consumer Healthcare Inc. has a one year low of $62.35 and a one year high of $90.04. The stock has a market cap of $4.21 billion, a price-to-earnings ratio of 19.90, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. The stock has a fifty day moving average price of $82.86 and a 200-day moving average price of $78.79.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.
Insider Activity
In related news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now owns 17,157 shares of the company's stock, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.60% of the company's stock.
Wall Street Analysts Forecast Growth
PBH has been the topic of a number of recent research reports. Oppenheimer increased their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. Sidoti downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. Raymond James raised shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. Canaccord Genuity Group increased their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Finally, StockNews.com upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Tuesday, March 18th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $93.33.
View Our Latest Stock Analysis on Prestige Consumer Healthcare
About Prestige Consumer Healthcare
(
Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Featured Articles
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
